Moreover, COVID-19-associated coagulopathy is formally different from SIC and DIC, with a marked increase in soluble TF, yet less platelet, antithrombin, and fibrinogen consumption, and less fibrinolysis alteration. This evidence concerns the gene TF and blood coagulation disease.